❌

Reading view

There are new articles available, click to refresh the page.

On ADHD Medication & Addiction

A history of substance abuse often precludes a young patient with ADHD from receiving a prescription for stimulant medication. It’s a common precaution, but new research suggests withholding treatment may do more harm than good. In fact, withholding ADHD treatment may put young people at greater risk of health problems and other adverse outcomes.

A national study led by researchers at the Penn State College of Medicine found a striking treatment deficit among adolescents and young adults diagnosed with both ADHD and substance abuse disorder (SUD). Published in the Journal of the American Academy of Child and Adolescent Psychiatry, the study analyzed medical records from more than 1.2 million people ages 15 to 25 diagnosed with ADHD. Of those, nearly one in four also had an SUD.

When a young person with ADHD received an SUD diagnosis, they were significantly less likely to be prescribed ADHD medication, the study found. Ongoing stimulant prescriptions dropped by roughly 15% among this group, and new stimulant prescriptions fell by more than 17%.

Young people who continued receiving ADHD treatment had meaningfully better outcomes, with fewer emergency room visits, fewer hospitalizations, fewer accidental overdoses, and fewer suicidal thoughts and attempts. They were also more likely to continue with psychiatric care. Most strikingly, ADHD treatment was associated with an approximately 30% lower risk of death over five years.

[Watch: ADHD Treatment and Substance Use Problems – The Latest Research on Stimulants & SUD]

Benefits were seen with both central nervous system stimulants (e.g., Adderall, Ritalin) and non-stimulants (e.g., Strattera), though stimulants were associated with even greater reductions in certain adverse outcomes.

These findings directly challenge the assumption that stimulant treatment worsens substance use-related problems.

The ADHD-SUD Connection

Research suggests that up to half of people with ADHD may develop a substance use disorder at some point in their lives due to genetics and neurobiology. Impulsivity, poor emotional regulation, and difficulty thinking through consequences can increase vulnerability to substance use. Without effective treatment, some young people discover that substances temporarily quiet the mental restlessness or emotional pain that ADHD can cause.

When ADHD and SUD occur together, the stakes are significantly higher: We see elevated rates of emergency room visits, hospitalizations, accidental overdose, suicidal thoughts, suicide attempts, and higher mortality risk. Effective treatment is not optional. It is urgent.

[Self-Test: Could You Have a Substance Use Disorder?]

The Risks of Withholding Medication

Stimulants typically produce significant symptom improvement. However, they are also controlled substances with documented potential for misuse and dependence, a concern that becomes even more significant when substance use is already in the picture. Many families and clinicians share this unease, and it helps to explain why providers often hesitate to prescribe stimulants once substance use is diagnosed.

However, when ADHD goes untreated, serious consequences may follow. Untreated ADHD can drive academic failure, emotional dysregulation, and low self-esteem, all of which can fuel substance misuse. Effective ADHD treatment interrupts that cycle. Better symptom control helps young people make safer decisions, stay engaged in school or work, and participate more consistently in recovery programs. For some, ADHD medication may also reduce the urge to self-medicate.

The Bottom Line

While any controlled substance should be prescribed with caution to patients struggling with substance use, an SUD diagnosis should not automatically end access to evidence-based ADHD treatment. Every patient is different, and the right approach depends on the individual. What matters most is that the conversation between doctor and patient remains open, treatment is actively monitored, and care is coordinated across mental health and addiction specialists when needed.

Questions to ask a treatment team include:

  • What are the risks and benefits of each medication option?
  • How will treatment be monitored safely?
  • What warning signs should we heed?

The goal is not just symptom control; it is promoting safety, restoring functioning, and giving young people a genuine chance at a healthier future. If you have questions about your own treatment or your child’s, bring them to your clinicians. Advocate for comprehensive care. The evidence is on your side.


When Drug Testing Is Routine

Some ADDitude readers have told us that they were required to submit to regular drug testing as a condition of continuing to receive their ADHD stimulant medication prescription. Among the reasons: to monitor adherence, prevent misuse, or comply with controlled-substance monitoring guidelines.

Here are a few of the comments they shared:

β€œThe policy from my doctor was that I had to sign an agreement before she would prescribe medication, and if she ever felt that I was abusing it, she would give me a test. I haven’t been asked to take a test and it’s been three years since I signed on.”

β€œIt costs $150 every time they ask me for a urine test. It’s ridiculous.”

β€œI have to do a drug screen once a year in order to refill my Adderall prescription.”

β€œAs an adult, this policy has been required by my doctor to confirm that I am, in fact, taking my medicine. However, when I was younger and seeing a pediatrician, it was never required for me.”

Stimulant Treatment and SUD : Next Steps

Raman Baweja, M.D., is a professor of psychiatry and behavioral health and public health sciences at the Penn State College of Medicine in Hershey, Pennsylvania.


ADDITUDE IS HUMAN
Artificial intelligence does not create or edit any written content published by ADDitude. Our editorial team is 100% human, and our mission is simple: listen to and serve our readers with hand-crafted, expert-informed resources. To support ADDitude, please consider subscribing. Your readership and support help make our commitment possible. Thank you.

Do ADHD Medications Raise Blood Pressure?

ADHD medications, particularly stimulants, are the most effective treatments in all of psychiatry. In the short term, they significantly reduce ADHD symptoms; in the long term, they protect against a multitude of negative outcomes.

While these medications deliver clear benefits, concerns remain about their possible side effects – among them, potential cardiovascular issues associated with long-term use. There is high-quality research on stimulants and heart health, and here I will place these findings in context.

ADHD Meds and Heart Health

Most ADHD medications – stimulants and non-stimulants – have small average effects on blood pressure and heart rate after weeks or a few months of use.1 These findings are based on the results of more than 100 randomized controlled trials, the most rigorous type of clinical study. Blood pressure in medicated individuals appears elevated mainly during the daytime, suggesting that the cardiovascular system isn’t continuously stressed and may recover at night when the medication has worn off.2

[Read: Heart Health and ADHD – On Cardiovascular Risks and Treatments]

To clarify the connection between cardiovascular disease and extended use of stimulant or non-stimulant medication for ADHD, a comprehensive study followed more than 278,000 people with ADHD over 14 years.3 Three findings stand out from this research:

  • People who take ADHD medication long-term face a slightly increased risk for hypertension compared to those who do not take these medications.
  • Hypertension risk is dose-dependent; the higher the dose of medication, the greater the risk for high blood pressure.
  • Taking ADHD medication long-term does not increase risk for arrhythmia, heart attacks, or thromboembolism.

Q&A with Dr. Cortese
Q: Is there a certain age when stimulants are contraindicated?

No, there is no specific age group for which stimulants are no longer recommended. One of the big areas of research now is ADHD in adults in their 60s, 70s, and so on. There is evidence that ADHD itself is related to an increased risk of cardiovascular problems, regardless of the effect of medication. Also, older adults’ risk for cardiovascular events may be higher because of their age and other conditions they may have. Patients should always discuss their specific health history with their clinician.

Q: Can you clarify whether an increase in blood pressure elevates the risk of a heart attack?

You might think that if your blood pressure continues to be high, you may eventually stress your heart and have a heart attack at some point. This is a serious and plausible concern. However, the data from the research are very clear. There is no significantly increased risk of heart attack at the group level.

In one study, blood pressure was measured over 24 hours with a special machine. Researchers observed that the blood pressure values were higher when the medication was in the system during the day. At night, blood pressure values returned to normal. This is very reassuring.

Guidelines for Professionals

High quality, rigorous research indicates that, at a group level, ADHD medication use may slightly increase the risk for high blood pressure, but not for other cardiovascular events. Given the clear benefits these medications provide – from improved academic function and protection against injury to reduced mortality – the risk-benefit ratio is reassuring for people who take ADHD medications.

That said, all decisions regarding ADHD medication use should consider the individual’s pre-existing or familial cardiac conditions and be made in consultation with a cardiovascular specialist. Other guidelines include the following:

  • Monitor blood pressure and pulse before and during ADHD treatment with all medications, not just stimulants.
  • Use the minimum effective dose of ADHD medication.
  • High blood pressure is not an absolute contraindication to ADHD medication, If hypertension is observed after starting medication, decrease the dose or stop the medication and refer the patient to a specialist who can check for and treat hypertension. The patient may be able to resume the ADHD medication after treatment. Hypertension can also be treated before starting ADHD medication.
  • Taking medication for high blood pressure is not a contraindication for ADHD medication. It is acceptable to take medication for ADHD in addition to medication for hypertension so long as blood pressure is stabilized and monitored.

ADHD and Heart Health: Next Steps

Samuele Cortese, M.D, Ph.D., is a professor at the University of Southampton in the United Kingdom and an adjunct professor at New York University. He was part of a team that created a platform on the latest ADHD research and evidence-based interventions at ebiadhd-database.org


ADDITUDE IS HUMAN
Artificial intelligence does not write or edit any content published by ADDitude. Our team is 100% human, and our mission is simple: listen to and serve our readers with hand-crafted, expert-informed resources. To support ADDitude, please consider subscribing. Your readership and support help make our commitment possible. Thank you.

Β 

Sources

1 Farhat, L. C., Lannes, A., Del Giovane, C., Parlatini, V., Garcia-Argibay, M., Ostinelli, E. G., Tomlinson, A., Chang, Z., Larsson, H., Fava, C., Montastruc, F., Cipriani, A., Revet, A., & Cortese, S. (2025). Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet. Psychiatry, 12(5), 355–365. https://doi.org/10.1016/S2215-0366(25)00062-8

2Buitelaar, J. K., van de Loo-Neus, G. H. H., Hennissen, L., Greven, C. U., Hoekstra, P. J., Nagy, P., Ramos-Quiroga, A., Rosenthal, E., Kabir, S., Man, K. K. C., Ic, W., Coghill, D., & ADDUCE consortium (2022). Long-term methylphenidate exposure and 24-hours blood pressure and left ventricular mass in adolescents and young adults with attention deficit hyperactivity disorder. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 64, 63–71. https://doi.org/10.1016/j.euroneuro.2022.09.001

3Zhang, L., Li, L., Andell, P., Garcia-Argibay, M., Quinn, P. D., D’Onofrio, B. M., Brikell, I., Kuja-Halkola, R., Lichtenstein, P., Johnell, K., Larsson, H., & Chang, Z. (2024). Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases. JAMA psychiatry, 81(2), 178–187. https://doi.org/10.1001/jamapsychiatry.2023.4294

❌